%0 Journal Article
%T Unraveling the Impact of Direct-Acting Antivirals on Hepatitis-Linked Cirrhosis: A Comprehensive Analysis of Fibrosis, Child Score, and Disease Progression
%A Hajar Cherkaoui
%A Maryam Elkhayari
%A Maria Lahlali
%A Asmae Lamine
%A Nada Lahmidani
%A Amine Mekkaoui
%A Mounia Elyousfi
%A Dafr Allah Benajah
%A Mohammed El Abkari
%A Adil Ibrahimi
%A Hakima Abid
%J Open Journal of Gastroenterology
%P 203-212
%@ 2163-9469
%D 2024
%I Scientific Research Publishing
%R 10.4236/ojgas.2024.146023
%X The treatment of hepatitis C has undergone a significant boom since the advent of direct acting antivirals (DAA). Indeed, the interferon-ribavirin combination that has been used to treat hepatitis C has a virological response in only 45% of cases with significant side effects. The advent of direct-acting antivirals has changed the prognosis of cirrhotic patients with hepatitis C. DAAs have ensured a sustained viral response in the majority of patients. Our work aims to see the evolution of hepatitis C patients at the cirrhosis stage under DAA. We conducted a retrospective study over 15 years (January 2009, January 2024) including all patients with post-viral cirrhosis C, whom we divided into two groups: group A, cirrhotic patients who received ribavirin and interferon, and group B, patients on DAA. From January 2009 to January 2024, we conducted a study of 182 patients with viral hepatitis C, including 102 cirrhotic patients. The mean age was 55 years. 66% of patients were initially treated with the ribavirin interferon combination, while 34% received direct-acting antivirals (DAAs). Since the introduction of DAAs, the most commonly used regimens have been sofosbuvir/daclatasvir with or without ribavirin and sofosbuvir/ledipasvir with or without ribavirin. Group A achieved sustained virological response (SVR) in 60% of cases, with notable side effects. In Group B, SVR was 98.18%, with improved tolerability and fewer side effects than previous treatments. Fifteen patients developed hepatocellular carcinoma (HCC), with a significantly lower mortality rate in those treated with DAAs compared with pegylated dual therapy (p: 0.001).
%K Post-Viral Cirrhosis C
%K Pegylated Interferon
%K Direct Acting Antivirals
%K Sustained Viral Response
%K Child Score
%K Fibrosis
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=134027